Divalproex Sodium Tablet, Extended Release
Product Images NDC 68180-260

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 68180-260). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 1 (D95f9b1b F1e4 4ae4 A215 7317fb1ca565 01)

Chemical structure diagram of divalproex sodium, showing its molecular components including two valproate moieties and a sodium ion.*

FDA Label Image

Image 2 (D95f9b1b F1e4 4ae4 A215 7317fb1ca565 02)

A cumulative distribution plot comparing the percent reduction in CPS rate between Divalproex Sodium delayed-release and placebo across different percentages of patients. The graph features improvement and worsening along the vertical axis and percent of patients along the horizontal axis, illustrating treatment effects on CPS rate reduction.*

FDA Label Image

Image 3 (D95f9b1b F1e4 4ae4 A215 7317fb1ca565 03)

A line graph comparing the percentage reduction in CPS rate for high dose versus low dose Divalproex sodium delayed release. The x-axis shows percent of patients, and the y-axis shows percent reduction in CPS rate ranging from -100% to 100%, with improvement indicated upward and worsening downward. Two lines represent patient outcomes by dose.*

FDA Label Image

Image 4 (D95f9b1b F1e4 4ae4 A215 7317fb1ca565 04)

A bar graph comparing placebo with Divalproex Sodium Extended-Release Tablets. The placebo bar is lower, marked 0.6, while the Divalproex bar is higher, marked 1.2, with a significance indication of p=0.006. The graph measures an unspecified variable on the vertical axis.*

FDA Label Image

Image 5 (D95f9b1b F1e4 4ae4 A215 7317fb1ca565 05)

Label for Divalproex Sodium Extended-Release Tablets, USP 250 mg, oral extended-release tablets. The label includes the NDC number 68180-260-06, manufacturer Lupin Pharmaceuticals, and specifies a 30-tablet count. The label emphasizes once-daily dosing and valproic acid activity, with storage instructions and pharmacist dispensing information.*

FDA Label Image

Image 6 (D95f9b1b F1e4 4ae4 A215 7317fb1ca565 06)

Label for Divalproex Sodium Extended-Release Tablets, USP 500 mg by Lupin Pharmaceuticals, Inc. The label indicates the product contains 30 extended-release tablets with valproic acid activity. It includes dosing, storage instructions, and manufacturer details for Lupin Pharmaceuticals, Inc. and Lupin Limited.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.